Cited by 145Brain Metastases and TreatmentManagement of metastatic bone diseaseCancer survivorship and care

Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors.

Waki, Fusako, Ando, Masashi, Takashima, Atsuo, Yonemori, Kan, Nokihara, Hiroshi, Miyake, Mototaka, Tateishi, Ukihide, Tsuta, Koji +3 more·2009·Journal of Neuro-Oncology

Abstract

Background Leptomeningeal metastasis (LM) occurs in 4-15% of patients with solid tumors. Although the clinical outcomes in cancer patients have been improving recently, no standard treatment for LM has been established as yet. The purpose of this study was to identify the prognostic factors in patients with solid tumors with cytologically proven LM.Methods We retrospectively analyzed a series of 85 consecutive patients with cytologically proven LM who were treated between 1997 and 2005.Results The primary diseases were as follows; lung cancer (n = 36), breast cancer (n = 33), gastric cancer (n = 8), and others (n = 8). Forty-nine patients had brain metastasis at the time of diagnosis of the LM, and in 51 patients, MRI revealed meningeal dissemination in the brain or spine. The performance status (PS) was 0-1 in 26 patients and 2-4 in 59 patients. Thirty-one patients, including 19 with breast cancer, four with lung cancer, five with gastric cancer and three with other cancers, were treated by intrathecal (IT) chemotherapy. The response rate to the IT was 52% (95% confidence interval (CI): 41.4-62.6%). The median survival was 51 days (range, 3-759 days). A univariate analysis identified breast cancer, good PS (0-1), time to development of the LM (>1 year), and treatment by IT chemotherapy as being associated with a good prognosis, and multivariate analysis identified poor PS (HR: 1.72 (95% CI, 1.04-2.86) P = 0.04) and MRI-proven LM (HR: 1.82 (95% CI, 1.11-2.98) P = 0.02) as being associated with a poor prognosis.Conclusion In patients with poor prognostic factors, such as poor PS or MRI-proven LM, palliative therapy might be the most suitable treatment strategy.

Integrity signals

Registry

Crossref · 10.1007/s11060-008-9758-3

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Primary tumors of the meninges are quite rare, however, the leptomeninges is a relatively common site for contiguous extension of primary tumors of the central nervous system, paranasal sinuses and skull base origin or tumor metastasis which can lead to dissemination into the CNS parenchyma and poor prognosis.

    “Primary tumors of the meninges are quite rare, however, the leptomeninges is a relatively common site for by contiguous extension of primary tumors of the central nervous system, paranasal sinuses and skull base origin or tumor metastasis which can lead to dissemination into the CNS parenchyma and poor prognosis”

    From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Waki et al., 2009

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Waki, F., Ando, M., Takashima, A., Yonemori, K., Nokihara, H., Miyake, M., Tateishi, U., Tsuta, K., Shimada, Y., Fujiwara, Y., & Tamura, T.
Affiliations
National Cancer Center Hospital (JP)
Corresponding author
Waki, Fusako
Venue
Journal of Neuro-Oncology
Published
2008-11-29
Volume
93
Issue
2
Pages
205-212
ISSN
  • 0167-594X (ISSN-L)
  • 1573-7373
OpenAlex
W2152333631
Cited by
145
References
25
Citations by year
2026: 2 · 2025: 9 · 2024: 7 · 2023: 6 · 2022: 9 · 2021: 10 · 2020: 15 · 2019: 14 · 2018: 11 · 2017: 6 · 2016: 11 · 2015: 6 · 2014: 3 · 2013: 11 · 2012: 8
FWCI
5.22
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Neuro-Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Brain Metastases and Treatment
  • Health Sciences › Medicine › Surgery › Management of metastatic bone disease
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords
leptomeningeal metastasis, solid tumors, prognostic factors, intrathecal chemotherapy, performance status, breast cancer, lung cancer, gastric cancer, brain metastases, survival, palliative care
MeSH terms
Adult, Aged, Aged, 80 and over, Brain Neoplasms, Breast Neoplasms, Female, Humans, Lung Neoplasms, Male, Meningeal Neoplasms, Middle Aged, Neoplasm Metastasis, Neoplasms, Prognosis, Retrospective Studies, Spinal Cord Neoplasms, Stomach Neoplasms, Time Factors, Survival Analysis, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review